Your session is about to expire
← Back to Search
MB-102 for Chronic Kidney Disease
Study Summary
This trial is testing a new way to measure kidney function. The new way uses a dye to measure how well the kidney is filtering blood. The trial will compare this new method to the current standard method. The trial will also evaluate the safety of the new method and dye.
- Chronic Kidney Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there positions available for new participants in this research?
"This trial appears to be open, as reflected on clinicaltrials.gov. It was first advertised on 6/1/2022 and has since been updated on 6/22/2022."
In how many different geographic areas is this trial taking place?
"Patients can enroll at 5 different clinical locations such as Research by Design, LLC in Chicago, Carolina Phase I Research in Raleigh, Velocity Clinical Research in Edgewater."
How many people are signed up to participate in this clinical trial?
"In total, 220 individuals who meet the prerequisites will be needed to partake in this clinical trial at various research sites such as Research by Design, LLC located in Chicago, Illinois and Carolina Phase I Research situated in Raleigh, North carolina."
Has the MB-102 drug been cleared for use by the FDA?
"MB-102 has been evaluated for safety in multiple Phase 3 clinical trials, meaning that there is both efficacy and safety data available. Therefore, we have rated it as a 3 on our scale."
Share this study with friends
Copy Link
Messenger